CRINETICS PHARMACEUTICALS IN (CRNX) Forecast, Price Target & Analyst Ratings
NASDAQ:CRNX • US22663K1079
38.9 USD
-0.61 (-1.54%)
At close: Mar 5, 2026
38.9 USD
0 (0%)
After Hours: 3/5/2026, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CRINETICS PHARMACEUTICALS IN (CRNX).
Forecast Snapshot
Consensus Price Target
$86.34
+ 121.94% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate-$1.27
Revenue Estimate8.371M
ChartMill Buy Consensus
84.55%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$86.34
Upside
+ 121.94%
From current price of $38.90 to mean target of $86.34, Based on 22 analyst forecasts
Low
$55.55
Median
$89.76
High
$110.25
Price Target Revisions
1 Month
0.68%
3 Months
5.61%
Price Target Summary
22 analysts have analysed CRNX and the average price target is 86.34 USD. This implies a price increase of 121.94% is expected in the next year compared to the current price of 38.9.
The average price target has been revised upward by 5.61% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.55%
CRNX was analyzed by 22 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CRNX.
In the previous month the buy percentage consensus was at a similar level.
CRNX was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-01-12 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2026-01-08 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-01-06 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-07 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-09-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-29 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-09-29 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-26 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-26 | Baird | Maintains | Outperform -> Outperform |
| 2025-09-26 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-09-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-11 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Stifel | Initiate | Buy |
| 2025-02-28 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
| 2025-02-04 | Wolfe Research | Initiate | Peer Perform |
| 2025-01-22 | Jefferies | Upgrade | Hold -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-14 | Citigroup | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate-$1.27
Revenue Estimate8.371M
Revenue Q2Q2,218.84%
EPS Q2Q-22.18%
Number of Analysts14
Next Earnings Revisions
Revenue (1 Month)
9.64%
Revenue (3 Months)
29.36%
EPS (1 Month)
-0.57%
EPS (3 Months)
-0.65%
Next Earnings Summary
CRNX is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -1.27 USD and the consensus revenue estimate is 8.37M USD.
The next earnings revenue estimate has been revised upward by 29.36% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.013M -15.34% | 1.039M -74.11% | 7.696M 640.71% | 63.9M 730.30% | 178.59M 179.48% | 426.56M 138.85% | 951.73M 123.12% | 1.626B 70.85% | 2.533B 55.78% | 3.443B 35.93% | 4.723B 37.18% | |
| EBITDA YoY % growth | -221.51M -32.72% | -336.069M -51.72% | -512.879M -52.61% | -510.391M 0.49% | -437.778M 14.23% | -232.53M 46.88% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -222.608M -32.60% | -338.854M -52.22% | -516.769M -52.50% | -548.515M -6.14% | -409.012M 25.43% | -173.088M 57.68% | 135.97M 178.56% | 629.75M 363.15% | 1.367B 117.07% | 2.131B 55.89% | 3.079B 44.49% | |
| Operating Margin | -5,547.17% | -32,613.47% | -6,714.77% | -858.40% | -229.02% | -40.58% | 14.29% | 38.73% | 53.97% | 61.89% | 65.19% | |
| EPS YoY % growth | -3.70 -17.83% | -3.71 -0.27% | -4.94 -33.15% | -4.98 -0.75% | -4.27 14.19% | -1.76 58.85% | 0.35 119.93% | 3.93 1,022.20% | 8.37 113.02% | 12.64 50.97% | 19.88 57.30% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.27 -22.18% | -1.27 -3.54% | -1.37 0.52% | -1.42 -10.35% |
| Revenue Q2Q % growth | 8.371M 2,218.84% | 12.286M 1,091.66% | 17.099M 11,857.34% | 22.322M 262.31% |
| EBITDA Q2Q % growth | -109.795M 0.62% | -109.189M 14.18% | -121.372M 13.11% | N/A |
| EBIT Q2Q % growth | -133.216M -19.58% | -135.427M -4.89% | -149.236M -4.66% | -147.766M -10.55% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
18.03%
EPS Next 5 Year
22.83%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
304.35%
Revenue Next 5 Year
202.19%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
16.01%
EBIT Next 5 Year
N/A
CRINETICS PHARMACEUTICALS IN / CRNX Forecast FAQ
What is the average price target for CRINETICS PHARMACEUTICALS IN (CRNX) stock?
22 analysts have analysed CRNX and the average price target is 86.34 USD. This implies a price increase of 121.94% is expected in the next year compared to the current price of 38.9.
Can you provide the upcoming earnings date for CRINETICS PHARMACEUTICALS IN?
CRINETICS PHARMACEUTICALS IN (CRNX) will report earnings on 2026-05-06, after the market close.
What are the consensus estimates for CRNX stock next earnings?
The consensus EPS estimate for the next earnings of CRINETICS PHARMACEUTICALS IN (CRNX) is -1.27 USD and the consensus revenue estimate is 8.37M USD.
How many analysts have analysed CRINETICS PHARMACEUTICALS IN (CRNX)?
The number of analysts covering CRINETICS PHARMACEUTICALS IN (CRNX) is 22.